Four key points:
1. The system is designed for patients with progressive adolescent idiopathic scoliosis deformity, which can affect individuals from age 10 to 21.
2. During its decision-making process, the FDA evaluated data from patients treated with the system since 2012. The study demonstrated safety and clinical benefits for the non-fusion deformity correction.
3. Surgeons can treat patients with Lenke Type 1 and Type 5 curves in progressive AIS patients. The posterior dynamic deformity correction system acts as an “internal brace” for patients.
4. The system has a self-adjusting rod mechanism and motion-preserving polyaxial joints for postoperative corrections.
More articles on spine devices:
FDA grants Fast Track designation for DiscGenics’ cell therapy for disc generation
16 spine devices receive FDA 510(k) clearance for neurostimulation
Medtronic spine revenue up nearly 1% to $658M
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
